The aim of this study was to determine the feasibility of a remifentanil/dexmedetomidine/neuraxial block technique in infants scheduled for surgery lasting longer than 2 hours.
Methods:
Sixty infants (age 1-12 months) were enrolled at seven centers over 18 months. A caudal local anesthetic block was placed after induction of anesthesia with sevoflurane. Next, an infusion of dexmedetomidine and remifentanil commenced, and the sevoflurane was discontinued. Three different protocols with escalating doses of dexmedetomidine and remifentanil were used.
Results:
One infant was excluded due to a protocol violation and consent was withdrawn prior to anesthesia in another. The caudal block was unsuccessful in two infants. Of the 56 infants who completed the protocol, 45 (80%) had at least one episode of hypertension (mean arterial pressure >80 mm Hg) and/or movement that required adjusting the anesthesia regimen. In the majority of these cases, the remifentanil and/or dexmedetomidine doses were increased although six infants required rescue 0.3% sevoflurane and one required a propofol bolus. Ten infants had at least one episode of mild hypotension (mean arterial pressure 40-50 mm Hg) and four had at least one episode of moderate hypotension (mean arterial pressure <40 mm Hg).
Conclusion:
A dexmedetomidine/remifentanil neuraxial anesthetic regimen was effective in 87.5% of infants. These findings can be used as a foundation for designing larger trials that assess alternative anesthetic regimens for anesthetic neurotoxicity in infants.
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| INTRODUCTION
There is evidence that most general anesthetics induce neuronal apoptosis in animal studies. 1 Some studies have also demonstrated long-term behavioral and functional changes in the neurodevelopment of animals exposed to prolonged anesthesia in infancy. 2 There is, however, controversy over whether these animal data are relevant in the care of children undergoing general anesthesia. [3] [4] [5] The changes seen in preclinical studies are greatest with exposure to gamma-aminobutyric acid (GABA) agonists and N-methyl-Daspartate (NMDA) antagonists such as volatile anesthetics (eg, sevoflurane), propofol, midazolam, ketamine, and nitrous oxide.
There is less evidence for such changes with opioids (eg, remifentanil) and conflicting evidence with alpha-2 agonists (eg, dexmedetomidine), with neurodegeneration occurring with doses larger than those used clinically. [6] [7] [8] Furthermore, these preclinical studies showed a dose-response relation: higher doses of anesthesia (ie, longer anesthesia) are associated with more morphologic and functional changes.
Some, but not all, human cohort studies have shown an association between exposure to anesthesia in infancy or early childhood and subsequent changes in cognitive tests, school performance, or risk of developing neurodevelopmental disorders. [9] [10] [11] [12] [13] [14] [15] Results of recent studies 16, 17 are reassuring for most healthy children exposed
What is already known about this subject
Animal studies provided strong evidence that general anesthesia with drugs interacting at the N-methyl-Daspartate receptor and at the γ-aminobutyric acid (GABA) A receptor, increased neuroapoptosis, altered synaptogenesis, and resulted in abnormal neurodevelopment and performance.
What this study adds
This feasibility study found that an anesthetic protocol based on dexmedetomidine, remifentanil and caudal anesthesia was effective in 90% of infants studied.
to one brief anesthetic, but the MASK study reported evidence of an association between multiple anesthetics and decreased fine motor ability and processing speed. 18 Importantly, there is strong evidence for an association between surgery and poor neurodevelopmental outcome in infants having prolonged anesthesia for major surgery. 19 However in this population, there is likely to be strong The purpose of this pilot study was to determine the feasibility of using a dexmedetomidine/remifentanil/caudal-epidural block anesthetic in infants younger than 1 year of age, requiring 2-3 hours of urologic or lower limb surgery, in order to prepare for a definitive trial comparing neurodevelopmental outcomes after this regimen versus a volatile anesthetic based regimen. The primary aim of the study was to determine the frequency of having to abandon the protocol for any reason. Our secondary aims were to determine the frequency of having to administer low dose sevoflurane or other types of rescue treatments for signs of light anesthesia (defined as hypertension and/or movement). We also noted the frequency of having to provide rescue treatment for hypotension and/or bradycardia, the time to recovery after anesthesia, need for postoperative pain medication, and any other adverse events.
| MATERIALS AND METHODS
An Institutional Review Board approved the protocol in all participating institutions and written informed consent was obtained from subjects' parents.
We included infants, age 1 to 12 months (corrected for gestational age) and American Society of Anesthesiologists physical status I or II, undergoing lower abdominal/lower extremity surgery anticipated to require at least 120 minutes of anesthesia time, where the surgical incision would be covered with a caudal or epidural block.
Surgical procedures included hypospadias repair, lower abdominal surgery, or lower extremity surgery. We excluded patients ASA III or higher, those with any contraindication to caudal analgesia or inhalational anesthesia with sevoflurane, patients with planned postoperative admission to an intensive care unit, or those with planned tracheal intubation and postoperative mechanical ventilation.
| Anesthetic technique
Baseline blood pressure and heart rate were recorded, and anesthesia was induced with sevoflurane (up to 8%) in air/oxygen, for the purpose of intravenous (IV) line placement. Once an IV line was inserted, sevoflurane was discontinued, loading doses of remifentanil and dexmedetomidine were started, the airway was secured, and a caudal-epidural was placed in a sterile manner. The time of sevoflurane administration was not to exceed 10 minutes. Airway management technique was at the discretion of the anesthesiologist (endotracheal tube or laryngeal mask airway). Glycopyrrolate (5 mcg/ kg) was administered before the dexmedetomidine and remifentanil loading doses. Common neuromuscular blocking drugs (at recommended doses) were permitted for initial airway management. Endtidal CO 2 was maintained at 35-45 mm Hg.
Caudal or epidural analgesia was performed after induction and airway management. The caudal block was typically performed with a 22G Angiocath, the catheter was advanced past the sacrococcygeal ligament and secured in place. Bupivacaine 0.175%-0.25% or ropivacaine 0.2% was administered through a catheter that was also available for re-dosing if required. The agent, dose, and technique were at the discretion of the anesthesiologist. Epinephrine 1/ 200 000 could be added to the local anesthetic, but clonidine or opioids were not allowed as adjuvants.
The protocol included a staged approach where dexmedetomidine and remifentanil doses were reviewed by the Trial Steering
Committee after the first 20 infants were recruited. We started with a low dose of remifentanil and dexmedetomidine as our initial greatest concerns were bradycardia and hypotension. After the first review, the Committee suggested a further review after another 20 children. At each review, light anesthesia (hypertension and/or movement) was deemed to be a greater problem than hypotension and thus we ended up sequentially enrolling three sets of children with steadily increasing doses of remifentanil and/or dexmedetomidine.
Light anesthesia was defined as movement or hypertension (two subsequent recordings of mean arterial pressure (MAP) >80 mm Hg).
| Protocol version 1
Initially, 0.6 mcg/kg of dexmedetomidine over 10 minutes and 1 mcg kg of remifentanil over 1-2 minutes were administered as loading doses during induction. At the completion of the loading doses, infusions of dexmedetomidine 0.6 mcg/kg/h and remifentanil 0.1 mcg/kg/ min were started. The infusion rates could be increased or decreased within 50% of the starting dose for dexmedetomidine, and a maximum dose of 0.5 mcg/kg/min for remifentanil.
| Protocol versions 2 and 3
The Committee amended the protocol twice after 16 (version 2) and 23 subjects (version 3) had been enrolled (see Figure 1 ).
Dexmedetomidine was discontinued 15-30 minutes before the end of surgery and remifentanil was stopped after the last stitch.
Antiemetic agents, warming, and fluid administration were managed according to local protocols.
| Management of side effects
In the case of light anesthesia with hypertension, the rescue protocol included a remifentanil bolus of 0.25-0.5 mcg/kg followed by an In case of mild bradycardia (defined as two subsequent recordings of a heart rate <100 but >70 beats per minute over 1 minute in duration), atropine 10-20 mcg/kg or glycopyrrolate 5 mcg/kg was to be given and dexmedetomidine was to be decreased by 50% per the protocol. Moderate bradycardia was defined as HR <70 beats
occurred at the discretion of the anesthesiologist. If significant bradycardia persisted after treatment, the anesthesiologist was to abandon protocol and treat the patient at his/her discretion.
Patients were observed in the recovery room for 60 minutes.
Oxygen saturation and MAP were recorded continuously, and the Face, Legs, Activity, Cry, Consolability scale (FLACC) was scored every 5 minutes.
| Statistical analysis
Considering a 5% failure rate and a precision of 95% confidence inter- confidence interval calculated using the binomial exact method.
The trial was registered at ClinicalTrials.gov in Feb 2015, Reference Number NCT02353182.
Subjects were studied under US Food and Drug Administration
Investigational New Drug number 118058 for dexmedetomidine.
| RESULTS
Sixty patients were enrolled in this pilot, feasibility study between May 2015 and Oct 2016, from seven centers. (Table 1) . Two children were excluded shortly after enrollment: one subject received midazolam premedication, one withdrew consent. No data were collected from these infants. In 2/58 infants (3%, 95% confidence interval 0.4, 11.9%), the protocol was abandoned due to failure to place the caudal block and the infant had an anesthetic given at the discretion of the anesthesiologist (primary outcome). In these cases, no intraoperative data were collected. The remaining 56 infants were treated as per pro- The demographic and anesthetic related data for the 56 children with a functioning caudal or epidural block is presented in Table 1 . 
| Primary outcome
The protocol was abandoned in 2 of 58 (3.4%) patients due to caudal block placement failure. Once the block was placed, none of the remaining 56 infants required the protocol to be abandoned.
| Secondary outcomes
Six of the 56 infants who completed the protocol (10.7%) received low-dose rescue sevoflurane (0.2%-0.9%) for a mean duration 24 ± 27 minutes (three in protocol version 1, one in version 2, and two in version 3). There was no relationship between the type of local anesthetic and the need for sevoflurane rescue. One subject received rescue propofol, but not sevoflurane (in protocol version 3).
Rescue treatment for light anesthesia (movement and/or hypertension) was required for the majority of infants (45/56; 80.3%). Movement without hypertension was reported in 42 (75%) infants (Table 2) . Episodes of hypertension (defined as two subsequent recordings of MAP >80 mm Hg) were recorded in 20 (36%) infants (Table 3) . Movement and hypertension were observed in infants receiving all three protocols. (Table 4 There were 8 (14.3%) recorded episodes of mild bradycardia and one of moderate bradycardia. All infants with bradycardia received rescue treatment (Table 5) .
One patient reduced his heart rate to 53 bpm, which was considered significant bradycardia (defined as heart rate <70 bpm over 1 minute in duration). This episode occurred at the time of extubation and about 10 minutes after discontinuation of dexmedetomidine. The bradycardia resolved after atropine administration and due to its occurrence after discontinuation of dexmedetomidine, it was considered a vaso-vagal event and unrelated to the study protocol.
The time to recovery from anesthesia (defined as the time from last stitch to eye opening) was 7.7 ± 10 minutes and the mean time from last stitch to "ready for PACU discharge" was 75 ± 19 minutes.
The mean FLACC scores were <2 in all patients, but seven patients (12.5%) received postoperative analgesia. There was one episode of bradycardia observed 20 minutes after the patient arrived to PACU, which resolved with glycopyrrolate. One patient experienced hiccups throughout the procedure. There were no other adverse events.
| DISCUSSION
This pilot study demonstrated that with a functioning caudal or epidural block, 87.5% of infants could be given satisfactory anesthesia with remifentanil and dexmedetomidine, without the addition of other general anesthetics. We deliberately choose a conservative In some instances, the treating clinician did not strictly follow the rescue protocol for hypotension; eg, vasopressors were never given. Dexmedetomidine has an elimination half-life of 2 hours in adults; but clearance is reduced in neonates 22 and matures over the first year of life. These pharmacokinetics could prolong "wake-up"
and recovery times. 23, 24 The wake-up (7.7 ± 10 minutes from last stitch to eye opening) and recovery times (75 ± 19 minutes -"ready to discharge from PACU") found in our patients are in agreement with reports from previous studies that showed a small increase in recovery time that is unlikely to be clinically relevant. Positively, there was no evidence for excessive pain or slow awakening. The protocol was completely abandoned in only 2 of 58 cases (3%) due to caudal block failure, which is similar to the failure rate found in larger trials. 25 This could be construed as indicating that this tech- Mild bradycardia: two subsequent recordings of a heart rate <100 but >70 beats per minute over 1 min in duration; moderate bradycardia: two subsequent recordings of a heart rate <70 BPM over 1 min in duration.
